MedTrace Logo

The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery

NCT06230198 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4500

Last updated 2025-03-04

No results posted yet for this study

Summary

The TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a policy of crystalloid priming reduces RBC transfusion for patients undergoing cardiac surgery on cardiopulmonary bypass. It will also provide information about key parameters of the TheRAPy full-scale trial.

Conditions

  • Red Blood Cell Transfusion

Interventions

PROCEDURE

retrograde autologous priming (RAP)

sites follow an institutional policy of routine use of retrograde autologous priming (RAP) during cardiac surgery

PROCEDURE

Crystalloid priming

sites implement crystalloid priming use during cardiac surgery

Sponsors & Collaborators

  • Population Health Research Institute

    lead OTHER

Principal Investigators

  • Jessica Spence, MD, PhD · Population Health Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
10 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-04
Primary Completion
2026-01-31
Completion
2026-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06230198 on ClinicalTrials.gov